Huadong Medicine's Controlled Subsidiary Obtains IND Approval from NMPA for DR10624 Injection Targeting Hypertriglyceridemia

Source: Securities Times

People's Finance News, February 4thHuadong Medicine(000963) On February 4, Huadong Medicine Co., Ltd. announced that its holding subsidiary, Zhejiang Doer Biologics Co., Ltd. (referred to as "Doer Biologics"), had received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for DR10624 injection submitted by Doer Biologics has been approved, allowing the initiation of clinical trials for the indication of hypertriglyceridemia.